ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Avon Awards $16.2 Million To Cancer Centers, Others.

April 6, 2001

NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial

May 14, 2010

Cancer Centers Could Form Network for Genetics Research, NCI Says

April 12, 1996

Solomon Gard Loses Final Cancer Battle

February 12, 1982

In Brief: Shubik, Rhoads, Dixon Affiliations With Industry Lister By House Subcommittee

June 11, 1976

In Brief: NCI Gets $867 Million From Conferees; Grants To Be Funded At 41-42% Including Some Holdovers

July 29, 1977